Edition:
India

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

51.66USD
1:32am IST
Change (% chg)

$0.07 (+0.14%)
Prev Close
$51.59
Open
$51.84
Day's High
$52.45
Day's Low
$51.57
Volume
598,678
Avg. Vol
1,167,358
52-wk High
$72.31
52-wk Low
$49.51

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000... (more)

Overall

Beta: 0.84
Market Cap(Mil.): $52,210.45
Shares Outstanding(Mil.): 1,022.26
Dividend: 0.34
Yield (%): 2.64

Financials

  TEVA.N Industry Sector
P/E (TTM): 26.86 34.95 35.86
EPS (TTM): 1.92 -- --
ROI: 4.98 13.73 13.09
ROE: 6.40 14.86 14.34

BRIEF-Spectrum Pharma says unit, Teva enter settlement agreement

* Unit, teva pharmaceuticals usa, inc. Entered into settlement agreement to resolve patent litigation relating to Folotyn

25 May 2016

Allergan CEO says company is 'weeks away' from closing Teva deal

NEW YORK Allergan Plc Chief Executive Brent Saunders said on Monday the company expects to close the $40.5 billion sale of its generic medicines portfolio to Teva Pharmaceutical Industries Ltd in a matter of weeks, opening the door for new acquisitions.

23 May 2016

UPDATE 1-Allergan CEO says company is "weeks away" from closing Teva deal

NEW YORK, May 23 Allergan Plc Chief Executive Brent Saunders said on Monday the company expects to close the $40.5 billion sale of its generic medicines portfolio to Teva Pharmaceutical Industries Ltd in a matter of weeks, opening the door for new acquisitions.

23 May 2016

Allergan CEO says company is "weeks away" from closing Teva deal

May 23 Allergan Inc Chief Executive Brent Saunders said on Monday the company expects to close the $40.5 billion sale of its generic medicines portfolio to Teva Pharmaceutical Industries Ltd in a matter of weeks, opening the door for new acquisitions.

23 May 2016

BRIEF-Allergan CEO says company is "weeks away" from closing Teva deal

* Allergan CEO says company is free to do multibillion dollar deals after Teva transaction closes

23 May 2016

UPDATE 5-Allergan profit beats estimates, share buybacks planned

* Shares up 2.9 pct at $220.00 (Adds Breakingviews link, updates share price)

10 May 2016

BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceeds

* Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potential

10 May 2016

BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceeds

* Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potential

10 May 2016

BRIEF-Allergan announces share repurchase program of up to $10 bln

* Company expects to execute $4 - $5 billion in open market repurchases

10 May 2016

UPDATE 1-Teva Pharm's quarterly profit beats forecast, sees Actavis deal closing in June

TEL AVIV, May 9 Teva Pharmaceutical Industries' , the world's biggest generic drugmaker, reported better-than-expected first-quarter profits on Monday and said it still expected its $40.5 billion acquisition of Allergan's generic drug business to close in June.

09 May 2016

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF79.60 +0.25
Biogen Inc (BIIB.OQ) $282.79 +0.79

Earnings vs. Estimates